Phase 2b Study of Efficacy and Safety of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients
with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This
study will have 5 treatment arms (4 active and 1 placebo).